Please login to the form below
respiratory syncytial virus
This page shows the latest respiratory syncytial virus news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s Abrysvo RSV vaccine recommended by US CDC for infants
Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, that can help to protect infants through the active immunisation of pregnant women, has been backed by the US Centers for Disease Control ... RSV is a common respiratory virus that
Latest news
-
GSK’s Ojjaara receives FDA approval to treat myelofibrosis patients with anaemia
Designed to increase the efficiency of manufacturing processes and reduce environmental impact, the new unit will handle freeze-dried vaccines, including the company’s respiratory syncytial virus (RSV) vaccine, Arexvy.
-
Moderna shares positive phase 3 results for mRNA influenza vaccine candidate
both HA and neuraminidase antigens to target multiple proteins involved in the influenza virus life cycle. ... With [the] positive phase 3 flu results, along with previous results in COVID-19 and respiratory syncytial virus, we are now three for three on
-
GSK invests over $270m in vaccine manufacturing ahead of RSV vaccine launch
The investment follows the launch of the company’s new respiratory syncytial virus (RSV) vaccine, Arexvy.
-
Pfizer’s RSV vaccine granted EC approval to protect infants and older adults
Pfizer's respiratory syncytial virus (RSV) vaccine has been approved by the European Commission (EC) to protect both infants and older adults against RSV-caused lower respiratory tract disease (LRTD). ... RSV is a common contagious virus characterised by
-
Pfizer’s maternal RSV vaccine granted FDA approval to protect infants
Pfizer’s respiratory syncytial virus (RSV) vaccine has been approved by the US Food and Drug Administration (FDA) to protect infants through the active immunisation of pregnant individuals. ... RSV is a common contagious virus characterised by several
More from news
Approximately 25 fully matching, plus 61 partially matching documents found.
Latest Intelligence
-
Well-funded life sciences firms are making long-term progress – and their investors are too
Up to that point, the drug was being developed to treat respiratory viral infections in patients with COPD who are at risk of experiencing exacerbations, which can be deadly and typically ... challenge study, in this case respiratory syncytial virus (RSV)
-
COVID-19: the race to find a vaccine
In the absence of a knockout antiviral, researchers are trying to mitigate harmful effects of the virus. ... Scientists have since industrialised the concept, leading to the development of antibodies against Ebola and respiratory syncytial virus.
-
Getting multichannel marketing right
has encouraged people to knit hats and blankets for babies to alert people to respiratory syncytial virus.
-
Deal Watch March 2017
In order to focus its respiratory resources on products such as Symbicort and benralizumab, AstraZeneca has agreed that its product Tudorza (marketed for COPD) and Duaklir (in phase III for COPD) ... Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur.
-
Pharma deals during September 2014
Alios has an oral anti-viral in phase 2 for treatment of infant respiratory syncytial virus (RSV) which complements J&J's early stage programmes in RSV.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Dutch biotech Mucosis promotes Thomas Johnston to CEO
During the last 12 months Mucosis has completed a clinical proof of concept study in human influenza for Mimopath and advanced respiratory syncytial virus (RSV) candidate SynGEM into pre-clinical studies.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Top 10 benefits of virtual advisory boards: Save Time and Resources
- NIHR launches new framework to highlight health progress outcomes
- Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases
- UKHSA secures UK-based vaccine deal for future influenza pandemics
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments
- Landscape review reveals £1.1bn of UK funding for rare diseases
No results were found
PMHub
Evoke Kyne
Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
